ALAB vs CRDO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ALAB is the larger of the two ($32.13B market cap): the incumbent the market prices for continued execution (25.70x forward earnings, beta 3.86). CRDO is the smaller challenger ($19.36B), cheaper on forward earnings (10.60x): more room to run, but more to prove. If you believe in growth, ALAB fits: analysts expect its revenue to rise 67% next year, against 55% for CRDO. If you believe in paying less for profit, CRDO fits: it trades at 10.6x forward earnings, against 25.7x for ALAB.

ALAB vs CRDO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricALABCRDOWhat it tells you
Market cap$32.13B$19.36BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E25.7010.60Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E72.6536.52Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta3.863.29Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range21% of range7% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book16.067.09How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: CRDO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ALAB and CRDO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALAB and CRDO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALAB and CRDO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Astera Labs (ALAB) do?

Astera Labs makes purpose-built connectivity hardware and software for AI and cloud infrastructure. Its core products are Aries PCIe and CXL smart DSP retimers (which preserve signal integrity so data can travel farther and faster inside a server), Taurus Ethernet smart cable modules (for high-speed 400G and 800G links between racks), Leo CXL memory controllers (which enable memory expansion and pooling), and the newer Scorpio fabric switches (P-Series PCIe switches and the X-Series AI fabric switch for connecting large GPU clusters). The company makes money by selling these chips and modules to hyperscalers, AI accelerator vendors, and system builders, and pairs them with a software layer for diagnostics and fleet management, positioning itself as a connectivity platform, not a single-chip supplier.

Full ALAB guide

What does Credo Technology (CRDO) do?

Credo Technology designs high-speed connectivity products that move data inside and between AI and cloud data centers. Its best-known product is the active electrical cable (AEC), branded ZeroFlap, a copper cable with Credo's own chips built in that carries data over short distances more cheaply and reliably than optical cables; Credo also sells SerDes IP and chiplets, line-card and retimer ICs, optical digital signal processors (DSPs), and OmniConnect memory connectivity. The company makes money by selling these chips and cables, mostly to hyperscale cloud operators and the networking equipment makers that serve them, with AEC and integrated-circuit demand driving the recent ramp.

Full CRDO guide

ALAB vs CRDO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ALAB drivers: Rising connectivity content per AI cluster; The Scorpio fabric switch ramp.
  • CRDO drivers: AEC adoption inside AI racks; AI bandwidth growth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Customer concentration is significant, with a large share of revenue tied to a handful of hyperscalers and AI accelerator vendors, so the loss or slowdown of one large customer would be material. For CRDO, customer concentration is the central risk: a large share of revenue has come from a few hyperscalers, and in some quarters a single customer has represented the majority of sales, so an order pause or design loss at one account can move results sharply.

ALAB or CRDO: which should you pick?

If the story you believe is ALAB's (Rising connectivity content per AI cluster), ALAB is the more direct way to own it; if it is CRDO's (AEC adoption inside AI racks), CRDO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALAB and CRDO guides.

ALAB vs CRDO: the full fundamentals

ALAB. Astera Labs still trades at a premium on sales and earnings, but far less steep than earlier in 2026: the multiple on trailing sales has fallen from ~42x in October to ~21x as revenue kept climbing and the share price dropped about 37% from its mid-October level. The valuation depends on continued hyperscaler capex and successful product ramps like Scorpio; consensus expects 2026 revenue near $2.03 billion and 2027 near $3.39 billion, with 2027 EPS near $7.15. The 22 covering analysts carry a mean target near $344, far above the November 20 close.

CRDO. The fall from a 52-week high near $309 has compressed Credo's multiple sharply: about 36 times trailing earnings and roughly 11 times forward estimates, against price to sales near 12 times, versus 62 times trailing in October. Analysts model fiscal 2027 revenue of about $2.5 billion and EPS near $6.31, rising to about $9.71 in fiscal 2028, and nineteen covering analysts carry a strong-buy consensus with a mean target near $277. The stock remains highly sensitive to hyperscaler AI spending, AI-chip sentiment and any change at its largest customers; figures are approximate as of November 20, 2026.

Headline figures (approximate, November 2026): ALAB shows revenue (ttm) ~$1.56 billion (FY2025 was ~$852 million), revenue growth (q3 2026 yoy) ~154% (Q2 2026 was ~105%); Q4 guidance $730 million to $750 million, q3 2026 results Revenue ~$585 million vs ~$551 million expected; $1.32 non-GAAP EPS vs $1.19 expected; GAAP net income ~$183 million, margins (ttm) ~74% gross, ~25.5% operating, ~30% net; CRDO shows revenue (ttm) ~$1.59B, revenue (q1 fy2027, quarter to aug. 1, 2026) ~$479M, up ~115% YoY, non-gaap eps (q1 fy2027) ~$1.20 vs ~$1.17 consensus; net income ~$129M, next earnings December 1, 2026; consensus EPS ~$1.28 on ~$532M revenue (guidance $525M to $535M).

The bottom line: ALAB vs CRDO

ALAB and CRDO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALAB and CRDO exposure against your real portfolio. It is not an investment adviser.

Wondering how ALAB or CRDO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Astera Labs

Ask Walnut's AI anything about ALAB and see how it fits what you own.

FAQ

What is the difference between ALAB and CRDO?

+

Astera Labs makes purpose-built connectivity hardware and software for AI and cloud infrastructure. Credo Technology designs high-speed connectivity products that move data inside and between AI and cloud data centers. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ALAB or CRDO the better stock?

+

Neither is universally better. ALAB is the larger incumbent; CRDO is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ALAB or CRDO?

+

On forward P/E (as of November 2026), ALAB trades at 25.70x and CRDO at 10.60x, so CRDO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ALAB and CRDO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ALAB vs CRDO?

+

ALAB: Customer concentration is significant, with a large share of revenue tied to a handful of hyperscalers and AI accelerator vendors, so the loss or slowdown of one large customer would be material. Broadcom and Marvell are far larger and better-capitalized competitors in connectivity and custom silicon, and both can bundle or undercut on price. Demand is tied to AI data center capex, which is cyclical and could slow or pause. The stock also carries a premium valuation that prices in years of continued rapid growth, leaving little margin for execution stumbles. Expectations are now high: consensus 2027 revenue of ~$3.39 billion sits only about 15% above an annualized run rate at the Q4 guidance midpoint, so the debate has shifted to how much growth remains after the 2026 ramp. The 2026 trading range shows how quickly sentiment can move: the stock has swung between ~$98 and ~$499 over 52 weeks and fell ~28% in the month after a quarter that beat estimates, during a broader November sell-off in AI chip stocks. Insider selling has continued (one filing in October 2026 showed ~$4.7 million of shares sold), and the comparison set has widened to include Credo and optical suppliers as connectivity moves toward optics. CRDO: Customer concentration is the central risk: a large share of revenue has come from a few hyperscalers, and in some quarters a single customer has represented the majority of sales, so an order pause or design loss at one account can move results sharply. Credo competes with much larger and well-funded rivals, including Broadcom and Marvell, plus newer entrants like Astera Labs, all targeting the same connectivity sockets. Revenue is tied to AI data-center capex, which is cyclical and could slow if hyperscaler spending cools. The stock is highly sentiment-driven: it fell about 55% in the three months to November 20, 2026 even as revenue more than doubled year over year, and it has moved in step with Nvidia and Marvell during the November selloff in AI-chip names. The latest EPS beat was the smallest of the last four quarters, so the December 1, 2026 report is a test of whether growth holds near guidance. Insider share sales reported in October 2026 are another data point holders watch.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALAB or CRDO; figures are approximate and dated (as of November 2026). Verify current data before investing.